124 related articles for article (PubMed ID: 31475375)
21. EZH2 mutations are frequent and represent an early event in follicular lymphoma.
Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J
Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547
[TBL] [Abstract][Full Text] [Related]
22. Follicular lymphoma: are we ready for a risk-adapted approach?
Kahl BS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):358-364. PubMed ID: 29222279
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
[TBL] [Abstract][Full Text] [Related]
25. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
[TBL] [Abstract][Full Text] [Related]
26. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
Huet S; Szafer-Glusman E; Tesson B; Xerri L; Fairbrother WJ; Mukhyala K; Bolen C; Punnoose E; Tonon L; Chassagne-Clément C; Feugier P; Viari A; Jardin F; Salles G; Sujobert P
Am J Hematol; 2017 Jun; 92(6):515-519. PubMed ID: 28247997
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
[TBL] [Abstract][Full Text] [Related]
28. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
29. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
30. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.
Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N
J BUON; 2017; 22(2):487-494. PubMed ID: 28534374
[TBL] [Abstract][Full Text] [Related]
31. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
32. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
33. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
[TBL] [Abstract][Full Text] [Related]
34. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ; Chua N; Owen C; Joe-Uzuegbu O; Shakir H; Gogna P; Jarada TN; Brenner DR; Elia-Pacitti J; Ewara EM; Cheung WY
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e277-e285. PubMed ID: 37331847
[TBL] [Abstract][Full Text] [Related]
35. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.
O'Shea D; O'Riain C; Taylor C; Waters R; Carlotti E; Macdougall F; Gribben J; Rosenwald A; Ott G; Rimsza LM; Smeland EB; Johnson N; Campo E; Greiner TC; Chan WC; Gascoyne RD; Wright G; Staudt LM; Lister TA; Fitzgibbon J
Blood; 2008 Oct; 112(8):3126-9. PubMed ID: 18628487
[TBL] [Abstract][Full Text] [Related]
36. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.
Hellmuth JC; Louissaint A; Szczepanowski M; Haebe S; Pastore A; Alig S; Staiger AM; Hartmann S; Kridel R; Ducar MD; Koch P; Dreyling M; Hansmann ML; Ott G; Rosenwald A; Gascoyne RD; Weinstock DM; Hiddemann W; Klapper W; Weigert O
Blood; 2018 Oct; 132(16):1695-1702. PubMed ID: 30126979
[TBL] [Abstract][Full Text] [Related]
37. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
38. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.
Alhejaily A; Day AG; Feilotter HE; Baetz T; Lebrun DP
Clin Cancer Res; 2014 Mar; 20(6):1676-86. PubMed ID: 24449825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
